HSCS | Jotup

HeartSciences to Present at the LD Micro Invitational XIV Conference

Retrieved on:

Tuesday, April 2, 2024

Intelligence, Sofitel New York Hotel, HSCS, Conference

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York.

Key Points:

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York.
Mr. Simpson will also be hosting one-on-one meetings through the conference.

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Retrieved on:

Tuesday, March 26, 2024

Diabetes, Disease, Echocardiography, HSCS, Congress, Algorithm, Intelligence, Anesthesia, Patient, Mortality, LVDD, Society, Anesthesiology, Type, Use, American Society of Echocardiography, Medical device

Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.

Key Points:

Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.
In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled.
For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.
Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography.

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Retrieved on:

Thursday, March 14, 2024

Diabetes, Health, HSCS, Algorithm, Intelligence, Patient, Acquisition, Death, Cardiology, Completeness, Patent, Cardiovascular disease, FDA, Regulation, Police, Medical device

Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.

Key Points:

Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the third quarter fiscal 2024 ended January 31, 2024 and provided a business update.
HeartSciences has seen a fundamental change in its business opportunity since the end of the second fiscal quarter, with material improvements to its financial position and outlook.
During the third quarter fiscal 2024, the Company raised $9.2 million in net proceeds from sales of common stock and converted $1.1 million of debt to equity.
Complete financial results have been filed in the Company’s quarterly report on Form 10-Q with Securities Exchange Commission and is available on the Company’s website.

HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Retrieved on:

Tuesday, March 12, 2024

Diabetes, ARIC, HSCS, Cardiovascular disease, Algorithm, Learning, Risk, Intelligence, Patient, Atherosclerosis, HF, Death, Type 2 diabetes, Type, Use, T2DM, Cardiovascular Diabetology, Medicine, Medical device

Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.

Key Points:

Recent guidelines propose N-terminal pro-B-type natriuretic peptide (blood test for NT-proBNP protein marker) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes (T2DM) patients.
Accordingly, the study sought to evaluate whether an AI-ECG model based on MyoVista® wavECG™ features was superior to NT-proBNP, as well as a conventional screening tool—the Atherosclerosis Risk in Communities (ARIC) HF risk score, in SBHF screening among patients with T2DM.
This independent study provides evidence of the clinical and diagnostic capabilities of AI-ECG, and specifically our MyoVista wavECG technology, to potentially advance current standards of care for heart screening in diabetic patients.” said Andrew Simpson, Chief Executive Officer of HeartSciences.
“Globally cardiovascular disease accounts for approximately one-third of all annual deaths and AI-ECG is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, not only for diabetic patients, but also for a significant number of at-risk patients.

SaucerSwap increases total value locked by 300 percent in just one year with support from The Hashgraph Association (THA)

Retrieved on:

Wednesday, March 20, 2024

DEX, TVL, MEV, HSCS, Organization, Entrepreneurship, Risk, HTS, Non-fungible token, Decentralized finance, Ecosystem, Operation, THA, USD, Cryptocurrency

TVL on SaucerSwap increased from approximately $35 million to over $150 million at the beginning of March[1], a 300% surge in less than a year.

Key Points:

TVL on SaucerSwap increased from approximately $35 million to over $150 million at the beginning of March[1], a 300% surge in less than a year.
This all changed in 2023, when THA identified SaucerSwap as an innovative startup in the space and on-boarded the project to its Innovation Program.
Following the provision of funding support by THA, SaucerSwap underwent a period of rapid transformation and launched SaucerSwap V2 in the same year.
The support from The Hashgraph Association has been invaluable in our journey to build a cutting-edge, user-centric platform.

SaucerSwap increases total value locked by 300 percent in just one year with support from The Hashgraph Association (THA)

Retrieved on:

Wednesday, March 20, 2024

DEX, TVL, MEV, HSCS, Organization, Entrepreneurship, Risk, HTS, Non-fungible token, Decentralized finance, Ecosystem, Operation, THA, USD, Cryptocurrency

TVL on SaucerSwap increased from approximately $35 million to over $150 million at the beginning of March[1], a 300% surge in less than a year.

Key Points:

TVL on SaucerSwap increased from approximately $35 million to over $150 million at the beginning of March[1], a 300% surge in less than a year.
This all changed in 2023, when THA identified SaucerSwap as an innovative startup in the space and on-boarded the project to its Innovation Program.
Following the provision of funding support by THA, SaucerSwap underwent a period of rapid transformation and launched SaucerSwap V2 in the same year.
The support from The Hashgraph Association has been invaluable in our journey to build a cutting-edge, user-centric platform.

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

Retrieved on:

Wednesday, March 6, 2024

HSCS, AI, Intelligence, Growth, Patent, ECG, Medicine, Pharmaceutical industry

Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Canadian Intellectual Property Office Application No.

Key Points:

Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that the Canadian Intellectual Property Office Application No.
3,000,369 has been granted by the Canadian Intellectual Property Office.
Andrew Simpson, Chief Executive Officer of HeartSciences, commented, “Millions of conventional ECG’s are performed worldwide every week and AI-ECG technology is set to change medicine by providing the opportunity to detect heart disease earlier and more effectively, while reducing treatment costs.
We are pleased to receive this latest patent grant in Canada.

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Retrieved on:

Monday, February 26, 2024

Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.

Key Points:

Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
He served on the Board of Directors for the American Society of Echocardiography (ASE) and as the Chair of the ASE Telehealth and New Technology Taskforce.
In 2020, Dr. Sengupta was named a Richard Popp Excellence in Teaching Award recipient by the American Society of Echocardiography.
I look forward to helping HeartSciences further advance the field of AI in cardiology.”

HeartSciences Expands its Scientific Advisory Board

Retrieved on:

Monday, February 12, 2024

Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.

Key Points:

Southlake, TX, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Jordan B. Strom M.D., M.Sc., to its Scientific Advisory Board.
Strom has been assisting us in recent interactions with the FDA and we are delighted to welcome him to our Scientific Advisory Board as we prepare for FDA submission of our MyoVista device and cloud platform, in addition to algorithms licensed from the Icahn School of Medicine at Mount Sinai, New York.
Dr. Strom has expertise in AI-based medical devices and is a consultant to GE Healthcare, Phillips Healthcare, and Edwards Life Sciences.
HeartSciences is an innovator in this field, and I look forward to helping them unleash the potential power of AI-powered ECGs to help clinicians deliver timely and optimal care.

HeartSciences Appoints New Scientific Advisory Board Member

Retrieved on:

Thursday, February 1, 2024

Intelligence, Genetics, University, Cardiovascular disease, Machine learning, Diagnosis, FDA, Drug discovery, ECG, Doctor of Philosophy, Health, HSCS, Assistant, Patent, Algorithm, Data science, Medical device

Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.

Key Points:

Southlake, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the appointment of Benjamin Glicksberg, Ph.D. to its Scientific Advisory Board.
“We are delighted to welcome Dr. Glicksberg, an elite data scientist and an instrumental leader in the establishment of the AI-ECG program at the Icahn School of Medicine at Mount Sinai, New York (Mount Sinai) to HeartSciences’ Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
As part of this process, we are actively expanding our Scientific Advisory Board to include industry experts and broaden our outreach.
I am impressed by their proven track record of innovation and look forward to contributing to HeartSciences at the forefront of this field.”